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Abstract
Background & Aims—In 2015, a national Egyptian health issue survey was conducted to 
describe the prevalence of hepatitis C virus (HCV) infection. In this paper, we describe the HCV 
burden in 2015, compare the results with the national survey conducted in 2008, and discuss the 
implications of the new findings on prevention of HCV in Egypt.
Methods—A multistage probability sampling approach was used, similar to the national 
demographic survey conducted in 2008. More than 90% of sampled individuals complied with the 
interview and provided blood samples.
Results—In the 15–59-year age groups, the prevalence of HCV antibody was found to be 10.0% 
(95% CI 9.5–10.5) and that of HCV RNA to be 7.0% (95% CI 6.6–7.4). In children, 1–14 years 
old, the prevalence of HCV antibody and HCV RNA were 0.4% (95% CI 0.3–0.5) and 0.2% (95% 
CI 0.1–0.3) respectively. Approximately, 3.7 million persons have chronic HCV infection in the 
age group 15–59 in 2015. An estimated 29% reduction in HCV RNA prevalence has been seen 
since 2008, which is largely attributable to the ageing of the group infected 40–50 years ago 
during the mass schistosomiasis treatment campaigns. Prevention efforts may have also 
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contributed to this decline, with an estimated 75% (95% CI 6– 45) decrease in HCV incidence in 
the 0–19 year age groups over the past 20 years.
Conclusions—These findings can be used to shape future HCV prevention policies in Egypt.
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Hepatitis C Virus (HCV) infection is a major global health challenge; it is estimated that 
more than 80 million people are chronically infected worldwide, with 3–4 million new 
infections and 350 000 deaths occurring each year because of HCV-related complications 
(1–3). Egypt is the country with the highest HCV prevalence in the world; in 2008, the 
Egyptian Demographic Health Survey (EDHS), which was conducted on a large nationally 
representative sample, estimated the prevalence of HCV antibodies and HCV RNA, among 
the 15–59 year age group, to be 14.7 and 9.8% respectively. Based on the population census 
and the EDHS done in 2008, it was estimated that more than 6.8 million persons aged 15–59 
years had HCV antibodies, of which more than 4.5 million individuals had active HCV 
infection (4). In 2015, the Egyptian Health Issues Survey (EHIS) was done to re-estimate the 
prevalence of HCV infection in Egypt. In this paper, we describe the prevalence of HCV in 
Egypt in 2015, using measures of both HCV RNA, which indicates the burden of disease, 
and of HCV anti-body, which provides an estimate of past infection. We also compare the 
results of the two national surveys conducted in 2008 and 2015 in order to estimate national 
changes in prevalence and incidence, and discuss the implications of these findings on the 
national policy for HCV prevention and treatment in Egypt.
Materials and methods
Source of data
We obtained data from the EDHS 2008 (4) and EHIS 2015 (5), both of which were 
conducted by El-Zanaty and Associates with support from the United States Aid of 
International Development-sponsored DHS-7 project.
Sampling strategy
The national surveys in 2008 and 2015 were cross-sectional household surveys, where 
sampling weights were used to provide estimates considered representative of the Egyptian 
population on the basis of a complex, three-stage probability sampling approach. The two 
surveys provide estimates of HCV prevalence in Egypt for the country as a whole and 
broken down for the major administrative regions (Urban Governorates, Lower Egypt, 
Upper Egypt and the Frontier Governorates). In both EDHS 2008 and EHIS 2015, those 
aged 15–59 years were invited to participate, however, in EHIS 2015, children aged 6 
months to 14 years were also included (4, 5).
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Individuals within sampled households were invited and consented for participation. Basic 
demographic information was collected, including: age, gender, marital status, place of 
residence, level of education, work status and wealth status.
Laboratory procedures
The laboratory procedures applied in 2015 were similar to those in 2008 (4, 5). In 2015, 
consented individuals provided 7 ml of venous blood added to an EDTA vacutainer tube. In 
the field laboratory, the 2015 EHIS biomarker staff centrifuged the blood and transferred the 
serum to five microvials that were stored in liquid nitrogen tanks before being transferred to 
the Central Public Health Laboratory (CPHL) in Cairo. A hepatitis C testing algorithm used 
third-generation enzyme immunoassay (ELISA) to determine the presence of HCV 
antibodies. A more specific assay, the chemiluminescent microplate immunoassay (CIA) 
was used to confirm HCV antibody status for ELISA-positive samples and 5% of the 
ELISA-negative samples. Quantitative real-time PCR was used to test for HCV RNA in 
HCV antibody-positive samples to confirm active infections. A quality control procedure of 
retesting of approximately 10% of all samples was undertaken at the CPHL and a further 
external quality control was done at the Theodor Bilharz Research Institute, in Cairo, by 
retesting approximately 5% of the samples tested at the CPHL (5). The only key difference 
between this procedure and that of the previous survey is that, in 2008, the quality control 
measure (10% of samples retested) at CPHL was not carried out.
Statistical analysis
Comparisons were carried out for HCV antibody- and HCV RNA-positive tests, by 
estimating the absolute and relative risk reductions between the two surveys in comparable 
age groups. To calculate the 95% confidence interval for the risk difference, Newcombe–
Wilson’s method without continuity correction was applied (6). In order to estimate 
confidence intervals for the relative risk, we used the methods described by Armitage and 
Berry (7). The level of significance (P-value) was inferred to be less than 0.05 if the 
corresponding 95% confidence intervals for the relative and absolute effect measures were 
devoid of ‘zero’ (8). HCV virus clearance was estimated by finding the absolute difference 
between the proportion of HCV antibody and HCV RNA-positive participants, and dividing 
this by the proportion of HCV antibody-positive participants. Comparisons of HCV 
clearance between combined age groups in 2008 and 2015 were done using the chi-square 
test. In order to demonstrate the cohort effect, the 2008 DHS data were shifted forward; 7 
years were added to each participant’s age from the 2008 DHS survey and the HCV 
antibody and HCV RNA prevalence estimates were re-calculated using the new numerator 
and denominator in each age category. The estimated number of population positive for 
HCV antibodies and HCV RNA was calculated by multiplying the age- and gender-specific 
prevalence of 2015 by the population census of January 2015 categorised by age and gender.
Ethical considerations
No ethical approval was needed for the data analysis presented in this paper; the anonymised 
data is publically available online. El-Zanaty and Co is the responsible party for the ethical 
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considerations of the EDHS 2008 and EHIS 2015; verbal informed consent was obtained 
from all individuals aged 18 years and older and from married minors aged 15–17 years. For 
children less than 18 years, consent was obtained from the parent or child caretaker.
Results
In EDHS 2008, 4757 households including 12 780 individuals aged 15–59 years were 
identified for interview and blood testing. A total of 4662 households complied (98%), 12 
008 persons were interviewed (93.9%) and out of these, 11 126 persons provided blood 
samples for testing (92.7%). In EHIS 2015, 7649 households including 28 079 individuals 
were identified. A total of 7516 households complied (98.3%), and 27 549 persons (age: 1–
59 years) were interviewed (98.1%). Of the total 28 079 persons identified, 17 182 were 
aged 15–59 years, of which 16 671 were interviewed (97.0%) and out of these, 16 003 
provided blood samples for testing (96.0%). The remaining 10 897 persons identified were 
children aged 1–14 years, and of these, 10 878 (99.8%) were interviewed through their 
caregivers and 10 044 (92.3%) children provided blood samples for testing. Children 
therefore represented 39.5% of the total study population (those interviewed) in EHIS 2015. 
The characteristics of the two populations surveyed in EDHS 2008 and EHIS 2015 are 
presented in Table 1. For comparison purposes, we describe the age group of 15–59 years 
who were targeted in both surveys.
There was an overall significant reduction of 32 and 29% in the prevalence of HCV antibody 
and HCV RNA-positive individuals, respectively, between the DHS in 2008 and the EHIS in 
2015 (Table 2). The age-specific prevalence of HCV antibody and HCV RNA-positive 
individuals in 2008 and 2015 is presented in Table 2 and Fig. 1. The pattern of increased 
prevalence of HCV antibody and HCV RNA-positive persons with age was observed in both 
the 2008 and the 2015 survey. A statistically significant reduction in HCV antibody 
prevalence was observed in all age groups, and the greatest relative prevalence reduction 
(75%) was observed among those aged 15–19 years. A statistically significant reduction in 
HCV RNA-positive individuals was observed in all except the two age groups encompassing 
those 20–29 years of age. The age-specific prevalence of HCV antibody and HCV RNA-
positive individuals from 2008 shifted forward by 7 years is presented alongside the 2015 
prevalence estimates (Fig. 1). The current data (EHIS 2015) for the three oldest age groups 
(45–59 years) show a similar HCV clearance percentage when compared to the same age 
groups in the shifted-forward 2008 data (31.2% in 2015, 32.0% in the shifted 2008, P = 
0.756). For the cohort of children aged 1–14 years in 2015, the overall prevalence of HCV 
antibody and HCV RNA-positive individuals was 0.4% (95% CI 0.3–0.5) and 0.2% (95% CI 
0.1–0.3) respectively (Table 3).
A significant reduction of HCV antibody and HCV RNA-positive individuals was observed 
when looking at the overall prevalence in the Urban Governorates and, and for Lower and 
Upper Egypt Governorates (Fig. 2). No significant change in prevalence of either HCV 
antibody or HCV RNA positivity was observed in the frontier governorates.
Table 3 shows the age- and gender-specific prevalence of HCV antibody and HCV RNA-
positive persons in 2015, as well as the estimated total number of persons positive for HCV 
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antibody and HCV RNA in Egypt at this time. In the population aged 0–59 years, we 
estimated a total of 3 693 180 persons with chronic HCV infection (HCV RNA positive), 
and 5 309 555 persons with HCV antibodies.
Discussion
In 2015, HCV still affects a substantial proportion of the Egyptian population, where it is 
estimated that, in the 1–59-year age group, 5.3 million persons are positive for HCV 
antibodies and, of these, approximately 3.7 million (69.5%) are HCV RNA positive. This is 
an underestimate of the total human HCV reservoir in Egypt because older age groups (> 59 
years) were not included in the EHIS 2015. This recent survey shows a similar 
epidemiological pattern of increased HCV antibody prevalence with age as did the EDHS 
2008. This phenomenon was described in many studies (9, 10) and is because of the 
continuing exposure and risk of infection with age (11), while the proportion of persons with 
HCV infection who go on to develop severe disease and die of it remains low until 30 years 
after infection; the rate of progression to cirrhosis is estimated at 7% after 20 years of being 
infected (12). The increase in HCV antibody prevalence with age is therefore demonstrating 
the cumulative HCV incidence over time until HCV-related mortality becomes manifest.
This study shows a significant reduction in the overall prevalence of HCV antibody from 
14.7 to 10.0%, and HCV RNA from 9.9 to 7.0%, between 2008 and 2015 among those aged 
15–59 years. The main explanation for this marked reduction in HCV prevalence is the 
disappearance of the group infected during the mass schistosomiasis treatment campaign 
with reused syringes (1960s through early 1980s) to outside the age range covered by the 
survey (i.e. those older than 59 years) (13, 14). Indeed, as demonstrated in Fig. 1, the age-
specific HCV antibody and HCV RNA prevalence for 2015 matches well with the 2008 
prevalence estimates shifted by 7 years, suggesting that the ageing of the infected cohort, the 
so-called ‘cohort effect’, is the driving mechanism underlying the HCV age distribution; this 
was also demonstrated in the earlier reduction of HCV antibody prevalence from 30% in 
1996 (14) to 14.7% in 2008 (4).
In order to see whether or not a decrease in HCV incidence may have also been a contributor 
to the reduction in HCV prevalence, the most interesting age groups to look at are those less 
than 20 years of age; persons who were not affected by the mass treatment campaigns and 
for whom HCV-related mortality remains low. If we assume that mother-to-child HCV 
transmission is a negligible source of infant infection, as suggested by the <0.5% HCV 
antibody prevalence in the 1–4-year age group, then the HCV antibody prevalence at age 19 
indicates the cumulative incidence over the past 20 years. In 2008 and 2015, the prevalence 
of HCV antibodies in those aged 15–19 years was 4.1 and 1.0%, respectively; the percentage 
of relative risk reduction was 75% (95% CI 64–85), implying a very substantial reduction in 
HCV incidence in the past 20 years in this age group. Furthermore, the prevalence of HCV 
antibody (0.4%) and HCV RNA-positive persons (0.2%) observed in EHIS 2015 among the 
age group 1–14 years is low compared to several studies conducted in early 2000s, which 
described the HCV antibody prevalence to be ranging from 2 to 7% in children under 10 
years in rural areas of the Nile Delta (15–17).
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This change in incidence in the younger age groups could possibly be because of the various 
public health interventions implemented by the Ministry of Health and Population and its 
partners since 2008. In this time, several efforts have been made to promote and expand the 
infection prevention and control programmes beyond Ministry of Health and Population 
hospitals, particularly to the university hospitals. Auto disabled syringes were introduced to 
the routine immunisation sector in 2008 in order to promote safe injection practices among 
children. Safe blood transfusion activities, including policies and guidelines, have been 
intensified since 2009. Raising the awareness of the public, by targeting universities and 
schools to improve their understanding on the epidemiology and prevention of viral 
hepatitis, was also carried out. Pre-service education targeting healthcare staff has been 
carried out since 2008 to enforce the concepts of safe healthcare and prevention of blood-
borne pathogens.
One may question whether the national treatment programme, which managed to treat more 
than 350 000 persons in the past 7 years (18) using pegylated interferon and ribavirin (19), 
has had an impact on HCV prevalence figures. In such a case, it would be expected that 
cured patients would have cleared HCV RNA, but kept HCV antibodies. Therefore, the 
impact would be seen through an increase in HCV clearance percentage in the age groups 
most targeted by the national treatment programme. Owing to established approximate 50% 
cure rates of the combination of pegylated interferon and ribavirin (20), only half of these 
persons (i.e. 175 000) would have cleared their HCV infection after treatment. The national 
treatment programme prioritises persons with more advanced forms of liver disease, and 
therefore, at least half of the beneficiaries of this service are in their 40s or 50s. Indeed, in a 
group of 3235 patients treated for HCV in a hospital run by the Ministry of Health in Cairo, 
between 2007 and 2011, the mean age was 41 years with a standard deviation of 
approximately 10 years (21). In order to see whether or not treatment has, as of yet, had an 
impact on lowering the prevalence of persons with HCV RNA in Egypt, we can see whether 
or not there has been increased clearance in the four older age groups (i.e. encompassing 40–
59 years) over the past 7 years. If we assume that around half (87 500) of the total persons 
cured was in the 40–59-year age group, and considering that we have estimated 2.87 million 
persons with HCV antibodies in the same age group in 2015 (Table 3), we would have 
expected to see around a 3% higher clearance percentage in this group, in comparison with 
2008. However, an increase in clearance in these older age groups was not observed when 
comparing data from 2015 and the shifted-forward 2008 data. Indeed, it would require 
around 4000 anti-HCV-positive persons in this age group, in each data set, in order to have 
enough power to demonstrate this expected 3% difference; unfortunately, the anti-HCV 
population examined in this survey was much lower than that.
Treatment may show a larger impact in the near future as it is expected that emphasis will be 
put on an upscale of treatment of infected persons to prevent long-term complications (22), 
particularly considering that new direct-acting antiviral (DAA) drugs were approved for the 
treatment of HCV by the U.S. Food and Drug Administration (FDA) in late 2013, and then 
introduced into Egypt in late 2014. These new treatment regimens have reduced treatment 
duration to 12–24 weeks, decreased side effects and improved outcomes, with cure rates of 
85–95% across all patient populations (23, 24).
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Finally, differential migration and mortality of persons infected with HCV could have 
contributed to the reduced prevalence of both HCV antibody and HCV RNA-positive 
persons in 2015, as long as these rates are higher than infection incidence (25–27); these 
topics needs to be explored further.
The prevalence of HCV antibody and HCV RNA-positive individuals varied among 
governorates and was reduced in several geographical regions. Lower Egypt governorates, 
which are mostly rural in nature, still show a higher prevalence of HCV antibodies and HCV 
RNA when compared to urban governorates. This pattern of high HCV prevalence in rural 
areas is similar to previous multiple studies conducted in rural Lower Egypt governorates 
which showed a prevalence ranging from 14.4 to 18.5% (28–30). The frontier governorates 
did not show any significant change, however, this is possibly owing to the fact that the 
sample size was very low (n < 200), in both the 2008 and 2015 surveys.
Based on our findings in this study, we recommend the expansion of national health surveys 
in Egypt in order to include older age groups and allow further follow-up of elderly persons 
who have been the most affected by HCV and who, by the cohort effect, are being pushed 
out of view. Furthermore, there should be continued prioritisation of prevention programmes 
to increase the effects we are seeing in incidence in young age groups, with a focus on 
interventions which promote injection safety by reducing the frequency of unnecessary 
injections and syringe reuse. Interventions could include introduction of single-use materials 
and engineered safety devices, such as auto-disabled or auto-destructive syringes into the 
curative sector. Expansion of infection prevention and control programmes are of utmost 
importance, along with development of elaborate systems for delivering and renewing 
licenses of healthcare facilities to ensure continuity of safe procedures and application of 
standard precautions. Other analyses of the EHIS data should be done, using tools such as 
mathematical modelling, in order to properly estimate and explain changes in HCV 
incidence in Egypt; this could lead to further evidence-based recommendations related to 
prevention and control efforts. Finally, access to treatment should be a priority, and although 
economic constraints are faced by the country, treatment has been shown to be cost-effective 
in this context (31, 32) and focused, early treatment strategies may be effective in supporting 
prevention measures and reducing transmission (33).
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• There has been an approximate 30% decrease in HCV prevalence in 
Egypt between 2008 and 2015.
• This decline is mostly related to the ageing of the initially infected 
cohort; this phenomenon will be seen in most countries as the bulk of 
worldwide HCV infections took place between 1960 and 1980.
• Still, a 28% decline in incidence in younger age groups is estimated, 
most likely related to prevention efforts such as injection safety and 
awareness programmes.
• Treatment has not yet demonstrated an impact on decline of HCV 
prevalence in Egypt.
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(A) Age-specific prevalence of hepatitis C virus (HCV) antibody-positive persons in 2008 
and 2015 (left), then shifted (by 7 years) 2008 and 2015 (right). (B) Age-specific prevalence 
of HCV RNA-positive persons in 2008 and 2015 (left), then shifted (by 7 years) 2008 and 
2015 (right).
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Prevalence of hepatitis C virus antibody in the 2008 and 2015 Egyptian Demographic and 
Health Surveys.
Kandeel et al. Page 12

























Kandeel et al. Page 13
Table 1
Participant characteristics of Egyptian Demographic Health Surveys in 2008 compared to EHIS 2015
2008 2015
No. % No. %
Study population
  (15–59 years),
  total interviewed
12 008 100 16 671 100
Laboratory tested
  Yes 11 126 92.7 16 003 95.9
  No 882 7.3 668 4.1
Households, total sampled
  Interviewed
4953 100 7813 100
  Yes 4662 94.1 7516 96.2
  No 291 5.9 297 3.8
Age group (years), total 15–59
  15–19 2151 17.9 2713 16.3
  20–24 1960 16.3 2044 12.3
  25–29 1635 13.6 2433 14.6
  30–34 1322 11.0 2118 12.7
  35–39 1209 10.1 1917 11.5
  40–44 1148 9.6 1550 9.3
  45–49 1044 8.7 1424 8.5
  50–59 1539 12.8 2472 14.8
Gender, total
  Males 5718 47.6 7462 44.8
  Females 6290 52.4 9209 55.2
Marital status, total
  Never married 3863 32.2 4375 26.2
  Married 7588 63.2 11 372 68.2
  Widowed 400 3.3 329 2.0
  Divorce/separated 157 1.3 595 3.6
Residence, total
  Urban 5288 44.0 6206 37.2
  Rural 6720 56.0 10 465 62.8
Place of residence
  Urban governorates 2445 20.4 2267 13.6
  Lower Egypt 5213 43.4 8204 49.2
  Upper Egypt 4168 34.7 6081 36.5
  Frontier governorates 182 1.5 119 0.7
Education
  No education 2588 21.6 2652 15.9
  Some primary 1084 9.0 1459 8.8
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2008 2015
No. % No. %
  Primary complete/
    some secondary
2919 24.3 4552 27.3
  Secondary complete/
    higher
5417 45.1 8008 48.0
Wealth quintile
  Lowest 2042 17.0 3268 19.6
  Second 2442 20.3 3234 19.4
  Middle 2425 20.2 3212 19.3
  Fourth 2440 20.3 3436 20.6
  Highest 2659 22.1 3521 21.1
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